{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:21:35Z","timestamp":1778523695214,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2021,9,28]]},"abstract":"<jats:p>One of the mutations in the microtubule-associated protein tau, P301S, is causative for dominantly inherited frontotemporal dementia characterized by extensive tau pathology for which no licensed treatment is available. Hydromethylthionine is a potent tau aggregation inhibitor. We report treatment of an asymptomatic carrier of the P301S mutation using hydromethylthionine over a 5-year period beginning at the mean age of onset of clinical decline in the family. During the period of treatment, the rates of progression of cerebral atrophy were reduced by 61%\u201366% in frontal and temporal lobes, and the patient remained clinically asymptomatic.<\/jats:p>","DOI":"10.3233\/jad-210390","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T12:59:51Z","timestamp":1628254791000},"page":"1017-1023","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier"],"prefix":"10.1177","volume":"83","author":[{"given":"Peter","family":"Bentham","sequence":"first","affiliation":[{"name":"TauRx Therapeutics Ltd., Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger T.","family":"Staff","sequence":"additional","affiliation":[{"name":"Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bjoern O.","family":"Schelter","sequence":"additional","affiliation":[{"name":"TauRx Therapeutics Ltd., Aberdeen, UK"},{"name":"Institute for Complex Systems and Mathematical Biology, University of Aberdeen, Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Shiells","sequence":"additional","affiliation":[{"name":"TauRx Therapeutics Ltd., Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles R.","family":"Harrington","sequence":"additional","affiliation":[{"name":"TauRx Therapeutics Ltd., Aberdeen, UK"},{"name":"School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude M.","family":"Wischik","sequence":"additional","affiliation":[{"name":"TauRx Therapeutics Ltd., Aberdeen, UK"},{"name":"School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-210390_ref1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/00005072-199906000-00011","article-title":"Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau","volume":"58","author":"Bugiani","year":"1999","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-210390_ref2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(19)30394-1","article-title":"Age at symptom onset and death and disease duration in genetic frontotemporal dementia: An international retrospective cohort study","volume":"19","author":"Moore","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-210390_ref3","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1007\/s00415-005-0880-2","article-title":"Familial autosomal dominant cortico-basal degeneration with the P301S mutation in the tau gene: An example of phenotype variability [5]","volume":"252","author":"Casseron","year":"2005","journal-title":"J Neurol"},{"key":"10.3233\/JAD-210390_ref4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00415-003-1074-4","article-title":"Frontotemporal dementia and parkinsonism with the P301S tau gene mutation in a Jewish family","volume":"250","author":"Lossos","year":"2003","journal-title":"J Neurol"},{"key":"10.3233\/JAD-210390_ref5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/1531-8249(199911)46:5<708::AID-ANA5>3.0.CO;2-K","article-title":"FTDP-17: An early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation","volume":"46","author":"Sperfeld","year":"1999","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-210390_ref6","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1212\/WNL.55.8.1224","article-title":"A Japanese patient with frontotemporal dementia and parkinsonism by a tau P301S mutation","volume":"55","author":"Yasuda","year":"2000","journal-title":"Neurology"},{"key":"10.3233\/JAD-210390_ref7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1474-4422(14)70324-2","article-title":"Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: A cross-sectional analysis","volume":"14","author":"Rohrer","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-210390_ref8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.trci.2019.05.010","article-title":"Rates of lobar atrophy in asymptomaticmutation carriers","volume":"5","author":"Chen","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-210390_ref9","doi-asserted-by":"crossref","first-page":"e041632","DOI":"10.1002\/alz.041632","article-title":"mutations cause rapid progressive frontal temporal dementia: A case report","volume":"16","author":"Mao","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-210390_ref10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1212\/WNL.58.5.811","article-title":"Early-onset, rapidly progressive familial tauopathy with R406W mutation","volume":"58","author":"Saito","year":"2002","journal-title":"Neurology"},{"key":"10.3233\/JAD-210390_ref11","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"10.3233\/JAD-210390_ref12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer\u2019s disease: Cohort analysis as modified primary outcome in a Phase III clinical trial","volume":"61","author":"Wilcock","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-210390_ref13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JAD-191173","article-title":"Concentration-dependent activity of hydromethylthionine on clinical decline and brain atrophy in a randomized controlled trial in behavioral variant frontotemporal dementia","volume":"75","author":"Shiells","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-210390_ref14","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1016\/j.jmb.2018.08.010","article-title":"Cysteine-independent inhibition of Alzheimer\u2019s disease-like paired helical filament assembly by leuco-methylthioninium (LMT)","volume":"430","author":"Al-Hilaly","year":"2018","journal-title":"J Mol Biol"},{"key":"10.3233\/JAD-210390_ref15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41586-018-0454-y","article-title":"Structures of filaments from Pick\u2019s disease reveal a novel tau protein fold","volume":"561","author":"Falcon","year":"2018","journal-title":"Nature"},{"key":"10.3233\/JAD-210390_ref16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature23002","article-title":"Cryo-EM structures of tau filaments from Alzheimer\u2019s disease","volume":"547","author":"Fitzpatrick","year":"2017","journal-title":"Nature"},{"key":"10.3233\/JAD-210390_ref17","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1073\/pnas.85.13.4884","article-title":"Structural characterization of the core of the paired helical filament of Alzheimer disease","volume":"85","author":"Wischik","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-210390_ref18","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1152\/ajpcell.00512.2003","article-title":"Reduction and uptake of methylene blue by human erythrocytes","volume":"286","author":"May","year":"2004","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.3233\/JAD-210390_ref19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3233\/JAD-190772","article-title":"Concentration-dependent activity of hydromethylthionine on cognitive decline and brain atrophy in mild to moderate Alzheimer\u2019s disease","volume":"72","author":"Schelter","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-210390_ref20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/jpet.114.219352","article-title":"Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer\u2019s disease","volume":"352","author":"Baddeley","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/JAD-210390_ref21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-142874","article-title":"Tau aggregation inhibitor therapy: An exploratory Phase 2 study in mild or moderate Alzheimer\u2019s disease","volume":"44","author":"Wischik","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-210390_ref22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gmhc.2014.06.001","article-title":"Improvement in behavioral symptoms, motor impairment and activities of daily living in a patient with the behavioral variant of frontotemporal dementia under treatment with methylene blue","volume":"2","author":"Adler","year":"2014","journal-title":"Geriatr Ment Heal Care"},{"key":"10.3233\/JAD-210390_ref23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000351671","article-title":"Validation of the Addenbrooke\u2019s cognitive examination III in frontotemporal dementia and Alzheimer\u2019s disease","volume":"36","author":"Hsieh","year":"2013","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-210390_ref24","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1212\/WNL.0b013e3181e04070","article-title":"Clinical staging and disease progression in frontotemporal dementia","volume":"74","author":"Mioshi","year":"2010","journal-title":"Neurology"},{"key":"10.3233\/JAD-210390_ref25","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1109\/42.640753","article-title":"The boundary shift integral: An accurate and robust measure of cerebral volume changes from registered repeat MRI","volume":"16","author":"Freeborough","year":"1997","journal-title":"IEEE Trans Med Imaging"},{"key":"10.3233\/JAD-210390_ref26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jalz.2019.08.196","article-title":"Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration","volume":"16","author":"Olney","year":"2020","journal-title":"Alzheimers Dement"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-210390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:06:56Z","timestamp":1777370816000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-210390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":26,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jad-210390","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]}}}